Intelligence quotient improves after antiepileptic drug withdrawal following pediatric epilepsy surgery

Kim Boshuisen1, Monique M J van Schooneveld2, Cuno S P M Uiterwaal3

  • 1Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.

Annals of Neurology
|April 23, 2015
PubMed

Insights

Reducing antiepileptic drugs (AEDs) in children undergoing epilepsy surgery significantly improved postoperative intelligence quotient (IQ) scores and IQ gain. Complete withdrawal of AEDs showed the most substantial cognitive benefits, independent of other factors.

Area of Science:

  • Pediatric Neurology
  • Epilepsy Surgery
  • Cognitive Neuroscience

Background:

  • Antiepileptic drugs (AEDs) can cause cognitive side effects in children, impacting intellectual functioning.
  • Previous research indicated that the timing of AED withdrawal does not significantly affect long-term seizure outcomes.

Purpose of the Study:

  • To evaluate the impact of antiepileptic drug (AED) withdrawal on postoperative intelligence quotient (IQ) and IQ change (delta IQ) in children following epilepsy surgery.
  • To determine if reducing or stopping AEDs influences cognitive outcomes after surgery.

Main Methods:

  • Analyzed IQ scores from 301 children in the TimeToStop (TTS) cohort with pre- and postoperative neuropsychological assessments.
  • Used linear regression to assess the relationship between AED reduction and postoperative IQ/delta IQ, adjusting for confounders and a propensity score for AED withdrawal timing.

Main Results:

  • AED reduction at the time of the latest neuropsychological assessment significantly improved postoperative IQ and delta IQ.
  • Complete AED withdrawal was associated with greater improvements in IQ and delta IQ.
  • A higher number of reduced AEDs correlated with increased IQ and IQ gain after surgery.

Conclusions:

  • Initiating AED withdrawal, reducing the number of AEDs, and achieving complete AED withdrawal are linked to enhanced postoperative IQ scores and IQ gain in pediatric epilepsy surgery patients.
  • These findings are independent of other known determinants of cognitive outcome.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.4K